druggable

druggable

, drugable (drŭg′ă-bĕl)
1. Amenable to treatment with drugs or susceptible to alteration or manipulation with drugs.
2. In genetics, pert. to the ability of a molecule to regulate the function of an endogenous protein for the benefit of the organism.
druggabilitydrugability (-bil′ĭt-ē)
References in periodicals archive ?
Orum's cell-penetrating antibody platform is unique in that, it has the capacity to not only transform the landscape of druggable targets, but also overcome the limitation of cytosolic delivery of other therapeutic modalities, said Peter Park, Ph.D., Chief Scientific Officer of Orum Therapeutics.
The models will help identify potential druggable targets for treatment of indolent and aggressive thyroid cancers.
- What are the inflammatory-mediated ligands, receptors, signalling proteins and transcription factors that represent druggable targets in the Th17 helper cell?
The aim of the collaboration is the structural visualisation of novel druggable sites across multiple targets, to rapidly advance new therapies.
The companies say that their goal is the structural visualisation of novel druggable sites across multiple targets, to rapidly advance new therapies.
PhoreMost's next-generation phenotypic screening platform SITESEEKER reportedly probes the entire proteome in a live cell environment for novel druggable targets, enabling the systematic unmasking of cryptic druggable sites.
Pharmaceutical chemists provide a broad survey of the current status of techniques in drug delivery, pharmacological aspects of natural products, chemical mediators: druggable targets, and developments in medicinal chemistry.
The researchers are now investigating those genes that are active in leukemic stem cells in the hope finding druggable targets.
In addition, the event will focus on novel techniques that can be implemented within the field today that can identify new druggable targets and possibly open new therapeutic areas within the clinic.
In combination with a recently constructed laboratory at expanded premises on the Oxford Science Park, the acquisition of Kinetic Discovery has effectively transformed Exscientia into a 'full stack' AI-driven drug discovery firm that can go from gene to clinical candidate for any druggable target selected, Hopkins claims.